Saturday, October 6, 2007
Don't bet on IT this quarter
Posted by Admin at 6:55 PM 0 comments
Rakesh Jhunjhunwala - Question and Answers
Posted by Admin at 6:55 PM 0 comments
Maintain caution at higher levels
Posted by Admin at 6:55 PM 0 comments
Your new mobile network - DLF-AT&T
Posted by Admin at 6:55 PM 0 comments
Stocks you can pick
CMP: Rs 3,543.95
Target price: Rs 4,450
Bajaj Auto
CMP: Rs 2,612
Target price: Rs 3,065
Tata Power
CMP: Rs 944.10
Target price: Rs 1,198
PFC
CMP: Rs 207.90
Target price: Rs 242.70
Posted by Admin at 6:55 PM 0 comments
US economy: a tale of two parallel markets
With the Damocles' sword of a recession hanging over the US, why would an investor want to be exposed to that market? It's a strong argument, made even stronger by the falling dollar. Since all other currencies are appreciating against the dollar, non-dollar assets and currencies deliver easy returns. While the Bombay Stock Exchange Sensex went up 25.3% this year to 2 October, the Dollex (the BSE index that tracks the performance of Sensex scrips in dollar terms) has gained 36.5% over the same period.
But if investors are fleeing US assets, how do we explain the Dow rising to new highs? Surely, if the US is facing a recession or, at least, an economic slowdown and if its banks continue to be exposed to the aftermath of the subprime meltdown, there's little reason for investors to buy US equities. For an answer, it's necessary to look a little more closely at the behaviour of the US market. Closer inspection shows that the stocks that are performing well in the US market are those which have an exposure to the global economy. While consumer discretionary and financials, the sectors that are a play on the domestic economy, are laggards, materials, industrials, energy and technology, all of which are dependent on global demand, are doing well. As a matter of fact, with a depreciating dollar, exports should do very well indeed, as will those companies with large overseas operations. US market experts are drawing attention to the fact that there are two markets in the US, with very divergent performances.
Given the increasing decoupling between the US and the global economy, it may be possible for a section of the US market to reach new highs while the economy slows down.
The mirror image of that trend is the turning away from tech stocks in the Indian market. These stocks are at least partially a play on the US economy and the strength of the dollar and investors in India are applying the same logic that's causing US investors to flee US-centric stocks. Nor is this view limited to savvy investment banks and other institutional investors. A recent study by US fund tracker Lipper found that inflows into US domestic stock funds had fallen to levels not seen since 1994. On the other hand, Morgan Stanley recently raised a $1.5 billion (Rs5,925 crore) buyout fund for Asia, nearly treble the bank's previous Asia fund raised two years ago. Inflows into emerging market funds, as EPFR Global points out, were at an 85-week high during the fourth week of September. As EPFR observed, "it was US, Japan and Europe equity funds that provided the cash which flowed back into emerging markets funds. Combined redemptions from these three fund groups totalled $13.04 billion for the week as dollar weakness and fears about the fallout from the turmoil in the US subprime loan market continued to weigh on sentiment."
That's not all. Some equity strategists that are long on Asian stocks are advising their clients to short US and European financial stocks as a hedge. The outperformance of one asset class would mean the underperformance of the other.
CLSA strategist Christopher Wood writes in a recent issue of his newsletter Greed & Fear that "it makes sense to remain structurally overweight Asia and global emerging markets most particularly for genuine long-term investors such as pension funds. For a new round of Fed easing is akin to lighting a match to the Asian asset-reflation story". All the signs also point to several rounds of Fed rate cuts, thanks to the deep-seated problems in the US housing sector. Wood points out that the strengthening of currencies such as the euro could persuade the European central bank too to start cutting rates, using continued weakness in the credit markets as an excuse. That would open the floodgates into Asia even further. At the same time, Wood is also concerned about the impact of a US slowdown on commodities. He doesn't think that Chinese and Indian demand is enough to drive oil prices higher, for example. The current spike in commodity prices has more to do with a weaker dollar than with resurgent global demand. That's the reason Wood would "rather continue to own interest-rate sensitives in Asia ex-Japan geared to domestic demand rather than commodity cyclicals".
In the Indian market, it is sectors such as capital goods and banks geared to domestic investment demand that have been the leaders in this rally. Interest-rate sensitive stocks, which have lagged the market after rates started rising, have already moved up substantially from their lows. The bet that investors are making is that dollar inflows will be so strong that RBI will be forced to intervene in the forex markets to defend the rupee. That will unleash so much liquidity that, even if RBI does its best to mop up the liquidity, it may not be able to prevent interest rates from drifting down.
Globalization has led to dual markets everywherea set of stocks in every market tied to the domestic economy and another connected to the rest of the world. In the current rally, while those stocks that are connected to emerging markets will do well in the US market, stocks dependent on the domestic economy will outperform in the Indian market.
Posted by Admin at 6:26 PM 0 comments
KS Oils - Multibagger (KR CHOKSY)
1225 MT/day Crushing capacity
400 MT/day Refinery capacity
600 MT/day Solvent Extraction capacity
150 MT/day Vanaspati manufacturing capacity The Company has been growing at a rapid pace in the recent past and is expected to do so in the coming two-three years due to the economics of packaged edible oil sector.
Mustard Oil, which is involved in crushing and processing of Crude Mustard Oil often termed as Kachhi Ghani Mustard Oil. This is sold in loose as well in branded form under two brands, Double Sher and Kalash.
Refining division, which is involved in refining of Sunflower, Mustard and Soy Bean Oils. These oils are also sold in loose as well as branded form under KS and KS Gold brands.
Other division, which comprises of Vanaspati division and Solvent Extraction division. The Vanaspati division is involved in the processing of Vanaspati which is marketed solely in branded form under Gold and Gold Plus brands. The Solvent Extraction and others division is involved in extraction of oil from pressed mustard seeds and exports of Soy Meal.
loose bulk oil business leading to improved Return on Capital.
Joint venture in Malaysia
KS Oils has entered into joint venture in Malaysia with a stake of 49% for the purpose of investments / acquisitions of palm plantations / manufacture of crude palm oil. This joint venture would enable the company's long term objective of backward integration and to secure raw materials sourcing for its crude palm oil requirement from South East Asia. The joint venture company is also in the process of acquiring its first plantation in Malaysia for a negotiated consideration up to 11.50 Malaysian ringitt.
Net Sales of the company grew by 69% to Rs 366.33 crore from Rs 216.48 crore on the back of robust branded sales growth. Operating Profits also grew at a much faster pace compared to sales, 259%, due to increasing contribution of branded sales, which enjoy substantially higher margins vis-Ã -vis unbranded sales. PAT has increased by 177.4% from Rs 8.5 crore to Rs 23.6 crore. Interest cost increased as a percentage of sales.
At the CMP of Rs 72.50, KS Oils is trading at commodity valuations of EV/Sales of about 1.6x and EV/EBITDA of abou 14.9x its TTM Sales, which is extremely low compared to its peers in the FMCG industry.
The company operates in highly competitive oil business and any inability to pass on the increase in input costs could affect the margins.
KS Oils has managed to pass on any increase in raw material prices to its consumers inpsite of operating in a commodity business. Hence we believe the company would be able to do so in the future also.
Buoyant economic conditions leading to a tremendous rise in disposable income would lead to an increase in the per capita consumption (pcc) of oil. With global scale capacities created at low cost and presence in both premium and popular segments, KS OILS is best placed to tap this opportunity.
India with fastest growth in population is also the largest edible oil market in the world, but has one of the lowest pcc of oil (12kg as compared to 15kg in China and much higher in other developed countries). Low pcc offers tremendous scope for expansion of market as well as share of individual players like KS Oils, which has already witnessed a strong surge in its market share recently.
The growth in the branded segment has been extremely good contributing 61% of revenues. The small retail packs contributed around 30% to revenues. This segment is expected to keep its pace going.
With the competition from the unorganized segment expected to be eliminated with the introduction VAT, it will give KS Oils an advantage to capture the market.
Posted by Admin at 12:25 AM 0 comments
iGate Global Solutions leads gainers in 'A' group
Posted by Admin at 12:25 AM 0 comments
Abbott India
On October 1, the company reported sales of Rs 158 crore, a growth of 15% y-o-y for the third quarter ended August 2007 (Q3; year ends in November). The operating profit, at Rs 31 crore, grew faster by 26%. Margins, at 20%, were marginally higher y-o-y and have been stable over the last few quarters.
Abbott India's manufacturing presence in India is nil and product
Growth rates would have been better, had the company launched new products, which has not been the case.
Abbott had made a buyback offer last year, which got postponed and was completed in March 2007. A little over a month later, its board of directors approved another buyback offer aggregating to Rs 52 crore, at a price not exceeding Rs 650 per share, subject to approval of the members.
At Rs 579.60, the stock is trading at a PE of 15. Like most MNC companies, it has potential and investors may continue holding it as they may get an opportunity to exit with good returns in the event of a delisting.
Posted by Admin at 12:25 AM 0 comments
US Market struggles to register modest gains
After an entire day of almost flat trading, US stocks inched in the green territory in the final hour of trading and the indices ended little higher for the day today, Thursday, 4 October 2007. Investors digested weak economic reports and waited for tomorrow's crucial job and unemployment report. Eight out of ten economic sectors registered gains.
The Dow Jones industrial Average closed higher by 6.26 points at 13,974.31. The Nasdaq Composite Index, finished higher by 4.14 points at 2,733.57. S&P 500 finished higher by 3.25 points at 1,542.84.
Eighteen of thirty Dow stocks ended in green. Merck, United Technologies, P&G and CoCo-Cola led the group of Dow winners. IBM, Exxon Mobil, Caterpillar and Citigroup were the major Dow decliners.
In the morning, the Department of Labor reported that weekly initial jobless claims (number of Americans filing new claims for state unemployment insurance) for the week ended 28 September rose to 317k, up from the previous reading of 301k.
After that, the Department of Commerce reported that factory orders in August slipped 3.3%, as against the consensus estimate that called for a decrease of 2.8%. Orders had rose 3.4% in July.
Blockbuster result from RIMM fails to impress market
After opening higher for the day, stocks fell in the face of a larger-than-anticipated drop in factory orders and a modest rise in jobless claims. Ultimately, at the end, indices managed to close in the green.
But the economic reports were not much of market movers. It seemed that investors wanted to keep money away today and rather wait for tomorrow's unemployment report.
Investors waited for Research in Motion (RIMM), the maker of Blackberry devices, to report earnings after the close today. The company reported a second-quarter profit that beat expectations. Earnings per share registered 100% increase on a y-o-y basis. The company crossed the 10 million subscriber mark and predicted strength for the rest of the year. But the company's stock struggled in after-hours trading.
Among Indian ADRs, all ended in green barring ICICI Bank and Rediff.com. tata Motors and MTNL were the top gainers gaining 1.7% and 1.95 respectively.
Crude oil futures were back above $81/barrel today. Prices rose after dollar once again weakened today against its rival currencies. Crude-oil futures for light sweet crude for November delivery closed at $81.44/barrel (higher by $1.50/barrel or 1.8%) on the New York Mercantile Exchange.
On the New York Stock Exchange, 1.1 billion shares were exchanged, with advancing stocks outpacing decliners 5 to 3. Volume on the Nasdaq topped 1.1 billion shares, and advancers outran declining stocks 4 to 3.
For tomorrow, investors will have U.S. Labor Department's September jobs report before the market opens. Also garnering some attention will be the August Consumer Credit report.
Posted by Admin at 12:25 AM 0 comments
Ranbaxy Laboratories
For Zenotech, with annual revenues of Rs 13 crore and net profit of Rs 3.63 crore, the market value works out to Rs 460 crore at Rs 160 per share. A scrutiny of the synergies and the space in which Zenotech operates may provide an insight into its valuation and Ranbaxy's interest in it.
Zenotech is present in the niche area of biosimilars, wherein the global market size is estimated at $65 billion. These are generic, non-proprietary versions of drugs produced through biotechnological processes using living cell-based material. Ranbaxy does not have major presence at the moment in biosimilars and hence the stake hike will strengthen its foothold here, particularly since Zenotech's pipeline of offerings addresses a third of this global market.
Zenotech is also present in the oncology (cancer treatment) therapeutic segment (55% of its product portfolio), which is one of the fastest growing with the global market size estimated at $35 billion. This segment is expected to grow at a CAGR of 18% till 2010 (biologics included), which is a huge opportunity.
Zenotech also has a strong pipeline with seven biologics in the pipeline and two monoclonal antibodies ready to enter clinical trials. This will be synergistic with Ranbaxy's global presence, as the products, if successful, will be marketed through the latter's marketing and distribution network spread over 125 countries. Also, with Ranbaxy's backing, funding prospects of Zenotech will only be enhanced.
The prospects of biosimilars have been further enhanced with the opening up of developed nations like the US and in Europe, though in the absence of regulations for biogeneric products, how soon these revenues can flow in is a big question and remains a major risk.
Litigation (relating to patents, as seen in the past), too, remains a risk for companies like Ranbaxy.
Meanwhile, the company plans to hive of its own new chemical entity research division into a separate entity by 2008 and its current pipeline consists of two molecules in the clinics and six-seven other molecules in pre-clinical stages.
Ranbaxy has also announced the receipt of final approval from the US FDA to manufacture and market clarithromycin for oral suspension, which is a positive.
Ranbaxy has been an underperformer on the bourses and currently, at a PE of 25, the stock may be prescribed, only for those with a high risk appetite and a long-term perspective.
Posted by Admin at 12:25 AM 0 comments
Friday, October 5, 2007
Close: 18k so near yet so far !
Posted by Admin at 11:23 PM 0 comments
Strong US job data may lift Indian markets
Posted by Admin at 11:22 PM 0 comments
Bulls take a breather
Posted by Admin at 11:22 PM 0 comments
Market ends flat amid volatility
Posted by Admin at 11:22 PM 0 comments
Gains pared
Posted by Admin at 11:22 PM 0 comments
ITC's e-chaupal project
So how will ITC go about this phase of e-choupal? The first three pilot clusters for the fresh project have been set up near Chandigarh, Pune and Chandigarh. The pilots have a distinct advantage over places like Mhow, where ITC set up one its early e-choupal projects, since they are much better equipped with basic infrastructure. Linkages with the three cities are very good; all of them have an excellent road network, leading to the villages nearby.
Posted by Admin at 11:13 PM 0 comments
Firm global indices indicate positive outlook
Posted by Admin at 9:49 AM 0 comments
Power greed could 'shock' bears
Posted by Admin at 9:48 AM 0 comments